Fetih Akgul, MD | |
510 4th St South, Prairie St Johns Llc, Fargo, ND 58107 | |
(701) 476-7200 | |
Not Available |
Full Name | Fetih Akgul |
---|---|
Gender | Male |
Speciality | Psychiatry |
Experience | 39 Years |
Location | 510 4th St South, Fargo, North Dakota |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093807182 | NPI | - | NPPES |
13619 | Medicaid | ND | |
381G1AK | Other | MN | BCBS |
26215 | Other | ND | BCBS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | PT10106 (North Dakota) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Psj Acquisition Llc | 7012062235 | 20 |
News Archive
Gestational diabetes may place a much higher percentage of pregnant women - and their unborn babies - at risk for adverse outcomes than previously believed, according to a major international study presented at the American Diabetes Association's 67th Annual Scientific Sessions.
A new discovery about how cells move inside the body may provide scientists with crucial information about disease mechanisms such as the spread of cancer or the constriction of airways caused by asthma.
Researchers from Taiwan reveal that antiviral therapy for hepatitis C virus improves kidney and cardiovascular outcomes for patients with diabetes. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that incidences of kidney disease, stroke, and heart attack were lower in patients treated with pegylated interferon and ribavirin compared to HCV patients not treated with antivirals or diabetic patients not infected with the virus.
It probably isn't surprising to read that pharmaceutical drugs don't always do what they're supposed to. Adverse side effects are a well-known phenomenon and something many of us will have experienced when taking medicines.
K-PAX Pharmaceuticals is working with Stanford University and several other leading research institutions to perform a Phase II double-blind, placebo-controlled trial to evaluate the safety and efficacy of a currently available FDA-approved medication concurrently administered with a novel mitochondrial support product in order to identify a safe and effective treatment for the chronic fatigue and decreased alertness (i.e. brain fog) that commonly afflicts people with CFS.
› Verified 8 days ago
Entity Name | Psj Acquisition Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1679709802 PECOS PAC ID: 7012062235 Enrollment ID: O20090918000240 |
News Archive
Gestational diabetes may place a much higher percentage of pregnant women - and their unborn babies - at risk for adverse outcomes than previously believed, according to a major international study presented at the American Diabetes Association's 67th Annual Scientific Sessions.
A new discovery about how cells move inside the body may provide scientists with crucial information about disease mechanisms such as the spread of cancer or the constriction of airways caused by asthma.
Researchers from Taiwan reveal that antiviral therapy for hepatitis C virus improves kidney and cardiovascular outcomes for patients with diabetes. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that incidences of kidney disease, stroke, and heart attack were lower in patients treated with pegylated interferon and ribavirin compared to HCV patients not treated with antivirals or diabetic patients not infected with the virus.
It probably isn't surprising to read that pharmaceutical drugs don't always do what they're supposed to. Adverse side effects are a well-known phenomenon and something many of us will have experienced when taking medicines.
K-PAX Pharmaceuticals is working with Stanford University and several other leading research institutions to perform a Phase II double-blind, placebo-controlled trial to evaluate the safety and efficacy of a currently available FDA-approved medication concurrently administered with a novel mitochondrial support product in order to identify a safe and effective treatment for the chronic fatigue and decreased alertness (i.e. brain fog) that commonly afflicts people with CFS.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Fetih Akgul, MD 901 42nd St Sw, Apt # 202, Fargo, ND 58103 Ph: (701) 306-9890 | Fetih Akgul, MD 510 4th St South, Prairie St Johns Llc, Fargo, ND 58107 Ph: (701) 476-7200 |
News Archive
Gestational diabetes may place a much higher percentage of pregnant women - and their unborn babies - at risk for adverse outcomes than previously believed, according to a major international study presented at the American Diabetes Association's 67th Annual Scientific Sessions.
A new discovery about how cells move inside the body may provide scientists with crucial information about disease mechanisms such as the spread of cancer or the constriction of airways caused by asthma.
Researchers from Taiwan reveal that antiviral therapy for hepatitis C virus improves kidney and cardiovascular outcomes for patients with diabetes. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that incidences of kidney disease, stroke, and heart attack were lower in patients treated with pegylated interferon and ribavirin compared to HCV patients not treated with antivirals or diabetic patients not infected with the virus.
It probably isn't surprising to read that pharmaceutical drugs don't always do what they're supposed to. Adverse side effects are a well-known phenomenon and something many of us will have experienced when taking medicines.
K-PAX Pharmaceuticals is working with Stanford University and several other leading research institutions to perform a Phase II double-blind, placebo-controlled trial to evaluate the safety and efficacy of a currently available FDA-approved medication concurrently administered with a novel mitochondrial support product in order to identify a safe and effective treatment for the chronic fatigue and decreased alertness (i.e. brain fog) that commonly afflicts people with CFS.
› Verified 8 days ago
Susan L Scarberry, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 700 1st Ave S, Fargo, ND 58103 Phone: 701-234-4036 Fax: 701-234-4160 | |
Charlotte Marie Andersen, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 510 4th Street S, Fargo, ND 58107 Phone: 701-476-7200 | |
Dr. Lawana Marie Burtnett, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 510 4th St S, Fargo, ND 58103 Phone: 701-476-7200 | |
Dr. Ravinda Samaraweera, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 700 1st Ave S, Fargo, ND 58103 Phone: 701-234-4036 Fax: 701-234-4160 | |
Dr. Timothy T Vo, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2624 9th Ave S, Southeast Human Service Center, Fargo, ND 58103 Phone: 701-298-4500 Fax: 701-298-4400 | |
Karis Antonia Stenback Irving, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2101 Elm St Ne, Fargo, ND 58102 Phone: 615-918-0639 Fax: 612-749-3990 | |
Amna Masood, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 736 Broadway N, Fargo, ND 58102 Phone: 701-234-2000 Fax: 701-234-2345 |